Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445877 in ICI-refractory Non-small Cell Lung Cancer
NCT07133425Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2025
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of SAR445877 in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2025; status: recruiting.
02
Drugs
SAR445877
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07133425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07133425.